Molecular structure of GW 280264X, CAS Number: 866924-39-2
GW 280264X (CAS 866924-39-2)
Alternate Names:
GW280264X GW-280264X benzyl N-[(5S)-5-[[(2R,3S)-3-[formyl(hydroxy)amino]-2-(2-methylpropyl)hexanoyl]amino]-6-oxo-6-(1,3-thiazol-2-ylamino)hexyl]carbamate Benzyl ((S)-5-((2R,3S)-3-(N-hydroxyformamido)-2-isobutylhexanamido)-6-oxo-6-(thiazol-2-ylamino)hexyl)carbamate SCHEMBL22889513
CAS Number:
866924-39-2
Molecular Weight:
575.70
Molecular Formula:
C28H41N5O6S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
GW 280264X (CAS 866924-39-2) References
- Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. | Ludwig, A., et al. 2005. Comb Chem High Throughput Screen. 8: 161-71. PMID: 15777180
- Involvement of ADAM10 in axonal outgrowth and myelination of the peripheral nerve. | Jangouk, P., et al. 2009. Glia. 57: 1765-74. PMID: 19455579
- Lung endothelial ADAM17 regulates the acute inflammatory response to lipopolysaccharide. | Dreymueller, D., et al. 2012. EMBO Mol Med. 4: 412-23. PMID: 22367719
- ADAM17 inhibition enhances platinum efficiency in ovarian cancer. | Hedemann, N., et al. 2018. Oncotarget. 9: 16043-16058. PMID: 29662625
- Inhibition of MMPs and ADAM/ADAMTS. | Malemud, CJ. 2019. Biochem Pharmacol. 165: 33-40. PMID: 30826330
- The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis. | Saad, MI., et al. 2020. Carcinogenesis. 41: 527-538. PMID: 31257400
- ADAM10 and ADAM17 proteases mediate proinflammatory cytokine-induced and constitutive cleavage of endomucin from the endothelial surface. | Yang, J., et al. 2020. J Biol Chem. 295: 6641-6651. PMID: 32193206
- ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to γδ T cell immunotherapy. | Dutta, I., et al. 2021. Cancer Lett. 496: 156-168. PMID: 33045304
- ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids. | Hedemann, N., et al. 2021. Cancers (Basel). 13: PMID: 33922533
- Neutrophil-like pH-responsive pro-efferocytic nanoparticles improve neurological recovery by promoting erythrophagocytosis after intracerebral hemorrhage. | Fan, L., et al. 2024. Theranostics. 14: 283-303. PMID: 38164152
Inhibitor of:
ADAM, ADAM10, ADAM19, ADAM7, ADAM8, ADAM9, MBLAC2, NET-7, TACE, TNF alpha, and TNFa-IP 8.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GW 280264X, 5 mg | sc-507540 | 5 mg | $720.00 |